Abeona Therapeutics price target raised to $27.50 from $25 at Alliance Global Partners

Alliance Global Partners raised the firm’s price target on Abeona Therapeutics (ABEO) to $27.50 from $25 and keeps a Buy rating on the shares. Abeona announced Q1 results following the recent news of their FDA approval for Zevaskyn, a gene therapy for recessive dystrophic epidermolysis bullosa, notes the analyst, who also points out that the company recently entered into an agreement to sell the Rare Pediatric Disease Priority Review Voucher it was granted for $155M, allowing for additional funding. The firm values Zevaskyn for RDEB at $24 per share and the remaining pipeline, which includes ABO-102 for Sanfilippo syndrome and three preclinical programs, and cash at $3.50 per share.